Current trends in the immunotherapy of metastatic and recurrent squamous cell carcinoma of the head and neck

The immune system plays a key role in the development and progression of head and neck squamous cell carcinoma. Understanding the dysregulation and blockage of the immune system of malignant tumors in this location can improve treatment outcomes. A special group is made up of patients who have a wid...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Opukholi golovy i shei Jg. 10; H. 3; S. 41 - 47
Hauptverfasser: Kostalanova, Yu. V., Ganina, K. A., Makhonin, A. A., Gabrielyan, A. G.
Format: Journal Article
Sprache:Englisch
Russisch
Veröffentlicht: ABV-press 16.11.2020
Schlagworte:
biomarkers
immunotherapy
nivolumab
pd-1
pd-l1
pembrolizumab
programmed cell death ligand 1
programmed cell death protein 1
ISSN:2222-1468, 2411-4634
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract The immune system plays a key role in the development and progression of head and neck squamous cell carcinoma. Understanding the dysregulation and blockage of the immune system of malignant tumors in this location can improve treatment outcomes. A special group is made up of patients who have a widespread process and relapse after chemotherapy with platinum drugs, because they have a very poor prognosis and limitations in the possibilities of further treatment. To date, the most important data relate to drugs acting on the PD-1 (programmed cell death protein 1)/PD-L1 (programmed death ligand 1) immune checkpoints, which are used by the tumor to block the immune system, which have allowed to increase the effectiveness of treatment. The article presents a clinical case demonstrating the effectiveness of the use of checkpoint inhibitors after the use of platinum preparations.
AbstractList The immune system plays a key role in the development and progression of head and neck squamous cell carcinoma. Understanding the dysregulation and blockage of the immune system of malignant tumors in this location can improve treatment outcomes. A special group is made up of patients who have a widespread process and relapse after chemotherapy with platinum drugs, because they have a very poor prognosis and limitations in the possibilities of further treatment. To date, the most important data relate to drugs acting on the PD-1 (programmed cell death protein 1)/PD-L1 (programmed death ligand 1) immune checkpoints, which are used by the tumor to block the immune system, which have allowed to increase the effectiveness of treatment. The article presents a clinical case demonstrating the effectiveness of the use of checkpoint inhibitors after the use of platinum preparations.
Author Ganina, K. A.
Gabrielyan, A. G.
Kostalanova, Yu. V.
Makhonin, A. A.
Author_xml – sequence: 1
  givenname: Yu. V.
  surname: Kostalanova
  fullname: Kostalanova, Yu. V.
  organization: Samara Regional Clinical Oncology Dispensary
– sequence: 2
  givenname: K. A.
  orcidid: 0000-0003-4944-2507
  surname: Ganina
  fullname: Ganina, K. A.
  organization: Samara State Medical University, Ministry of Health of Russia
– sequence: 3
  givenname: A. A.
  orcidid: 0000-0002-2182-5429
  surname: Makhonin
  fullname: Makhonin, A. A.
  organization: Samara Regional Clinical Oncology Dispensary; Samara State Medical University, Ministry of Health of Russia
– sequence: 4
  givenname: A. G.
  orcidid: 0000-0002-5321-6070
  surname: Gabrielyan
  fullname: Gabrielyan, A. G.
  organization: Samara Regional Clinical Oncology Dispensary; Samara State Medical University, Ministry of Health of Russia
BookMark eNo9kc1u1TAQhS1UJErpO1jdG8bJxI7ZoSuglSqxgbU1scc0bRIXO3fRtye5_ZmF53jk80k-81GcLXlhIa40fNbWdPCl2UppNL1qoAGlQbUKtUL7Tpw3qDdlWjzb9Ou7D-Ky1nsA0AZ7dM25mA7HUnhZ5bqdscpxkesdy3Gej0veVKHHJ5mTnHmlutI6BklLlIXDi6_-O9Kcj1UGniYZqIRxyTPtnh10xxRPjoXDwyfxPtFU-fKlX4g_P77_Plyr218_bw7fblXQxlmVnHXOWdMjkNMM3Ccbh1Z3FiA4h9vNYKOBuR2g6Yy1ISG66BAiui61F-LmmRsz3fvHMs5Unnym0Z8Gufz1VLavTOyHRBCYoGs7RqPjYAdOOgyOYkp90Bvr6zMrlFxr4fTG0-BPa_B7vH6P1-9r2OetR-3Rtv8BRjt-Rw
Cites_doi 10.1158/1055-9965.EPI-08-0347
10.1159/000357712
10.1016/S0140-6736(19)32591-7
10.1126/science.133.3449.307
10.1093/annonc/mdv268
10.3322/caac.21492
10.1126/science.aaa4971
10.1056/NEJMoa1602252
10.1016/S0140-6736(18)31999-8
10.1097/MOO.0000000000000448
10.1080/2162402X.2018.1498439
10.1016/S1470-2045(17)30245-0
10.1016/0964-1955(93)90007-2
10.1038/nature14011
10.1016/j.oraloncology.2016.10.007
10.1016/S1470-2045(16)30066-3
10.1038/nrclinonc.2017.101
10.1038/s41588-018-0312-8
10.1016/j.oraloncology.2018.07.005
10.1093/annonc/mdw226
10.1172/jci.insight.89829
10.1056/NEJMra0707975
10.1038/nature12213
10.3322/caac.21387
10.1186/s40425-019-0662-5
10.1186/s41199-018-0039-3
10.1038/s41416-018-0131-9
10.1056/NEJMoa0912217
10.1002/cncr.10654
10.2217/imt.10.32
10.1038/nature13954
10.1016/j.annonc.2020.08.1030
10.1038/nrc2982
10.1016/j.clon.2005.02.014
ContentType Journal Article
DBID AAYXX
CITATION
DOA
DOI 10.17650/2222-1468-2020-10-3-41-47
DatabaseName CrossRef
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
DatabaseTitleList CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2411-4634
EndPage 47
ExternalDocumentID oai_doaj_org_article_bfa0cea0535e461db7bef1cb9adff8c1
10_17650_2222_1468_2020_10_3_41_47
GroupedDBID 5VS
642
AAFWJ
AAYXX
ADBBV
ALMA_UNASSIGNED_HOLDINGS
BCNDV
CITATION
GROUPED_DOAJ
KQ8
ID FETCH-LOGICAL-c1697-f9799976840a91e0e8f7db315700c994f7d64210ee3b025677cf449d940d495f3
IEDL.DBID DOA
ISSN 2222-1468
IngestDate Fri Oct 03 12:45:30 EDT 2025
Sat Oct 25 06:35:15 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
Russian
License https://ogsh.abvpress.ru/jour/about/editorialPolicies#openAccessPolicy
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c1697-f9799976840a91e0e8f7db315700c994f7d64210ee3b025677cf449d940d495f3
ORCID 0000-0002-5321-6070
0000-0003-4944-2507
0000-0002-2182-5429
OpenAccessLink https://doaj.org/article/bfa0cea0535e461db7bef1cb9adff8c1
PageCount 7
ParticipantIDs doaj_primary_oai_doaj_org_article_bfa0cea0535e461db7bef1cb9adff8c1
crossref_primary_10_17650_2222_1468_2020_10_3_41_47
PublicationCentury 2000
PublicationDate 2020-11-16
PublicationDateYYYYMMDD 2020-11-16
PublicationDate_xml – month: 11
  year: 2020
  text: 2020-11-16
  day: 16
PublicationDecade 2020
PublicationTitle Opukholi golovy i shei
PublicationYear 2020
Publisher ABV-press
Publisher_xml – name: ABV-press
References ref13
ref35
ref12
ref34
ref15
ref14
ref36
ref31
ref30
ref11
ref33
ref10
ref32
ref2
ref1
ref17
ref16
ref19
ref18
ref24
ref23
ref26
ref25
ref20
ref22
ref21
ref28
ref27
ref29
ref8
ref7
ref9
ref4
ref3
ref6
ref5
References_xml – ident: ref3
  doi: 10.1158/1055-9965.EPI-08-0347
– ident: ref9
  doi: 10.1159/000357712
– ident: ref17
  doi: 10.1016/S0140-6736(19)32591-7
– ident: ref16
  doi: 10.1126/science.133.3449.307
– ident: ref11
  doi: 10.1093/annonc/mdv268
– ident: ref1
  doi: 10.3322/caac.21492
– ident: ref19
  doi: 10.1126/science.aaa4971
– ident: ref31
  doi: 10.1056/NEJMoa1602252
– ident: ref33
  doi: 10.1016/S0140-6736(18)31999-8
– ident: ref34
  doi: 10.1097/MOO.0000000000000448
– ident: ref5
  doi: 10.1080/2162402X.2018.1498439
– ident: ref35
  doi: 10.1016/S1470-2045(17)30245-0
– ident: ref14
  doi: 10.1016/0964-1955(93)90007-2
– ident: ref22
  doi: 10.1038/nature14011
– ident: ref32
  doi: 10.1016/j.oraloncology.2016.10.007
– ident: ref27
  doi: 10.1016/S1470-2045(16)30066-3
– ident: ref13
– ident: ref15
  doi: 10.1038/nrclinonc.2017.101
– ident: ref23
  doi: 10.1038/s41588-018-0312-8
– ident: ref30
  doi: 10.1016/j.oraloncology.2018.07.005
– ident: ref18
  doi: 10.1093/annonc/mdw226
– ident: ref20
  doi: 10.1172/jci.insight.89829
– ident: ref10
  doi: 10.1056/NEJMra0707975
– ident: ref24
  doi: 10.1038/nature12213
– ident: ref7
  doi: 10.3322/caac.21387
– ident: ref26
  doi: 10.1186/s40425-019-0662-5
– ident: ref4
  doi: 10.1186/s41199-018-0039-3
– ident: ref28
  doi: 10.1038/s41416-018-0131-9
– ident: ref6
  doi: 10.1056/NEJMoa0912217
– ident: ref8
– ident: ref12
  doi: 10.1002/cncr.10654
– ident: ref25
  doi: 10.2217/imt.10.32
– ident: ref21
  doi: 10.1038/nature13954
– ident: ref36
  doi: 10.1016/j.annonc.2020.08.1030
– ident: ref2
  doi: 10.1038/nrc2982
– ident: ref29
  doi: 10.1016/j.clon.2005.02.014
SSID ssj0001648492
Score 2.1245341
Snippet The immune system plays a key role in the development and progression of head and neck squamous cell carcinoma. Understanding the dysregulation and blockage of...
SourceID doaj
crossref
SourceType Open Website
Index Database
StartPage 41
SubjectTerms biomarkers
immunotherapy
nivolumab
pd-1
pd-l1
pembrolizumab
programmed cell death ligand 1
programmed cell death protein 1
Title Current trends in the immunotherapy of metastatic and recurrent squamous cell carcinoma of the head and neck
URI https://doaj.org/article/bfa0cea0535e461db7bef1cb9adff8c1
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2411-4634
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001648492
  issn: 2222-1468
  databaseCode: DOA
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA4iIl7EJ64vcvBatjFp0xxVXDzo4kFlbyVPKLpd7XYF_70zaV3WkxePCUwIk5D5viTzDSEXRmUQNAC5wfnoE5E5lhTWZkmujTZAQbiOedwv93I8LiYT9bhS6gv_hHXywJ3jhibo1HqNMiRe5MwZaXxg1ijtQihsJD6AelbIVLxdyUUhYkVkiH8wEZEXveKoBEgyXHbCJgH6hEdRIoBLyV_RaUXEP0ab0Q7Z7mEiveqmt0vWmsUe2XzoH8L3yVuvq0Tb-KeVVjUFJEcrzPboc6q-6CzQqW815gxVlura0QZv16Pd_GOhkfVTvLmnFisK1bOpRhscCI5oFy1qb18PyPPo9unmLukLJySW5UomAd_qFD6xpVoxn_oiSGc4Qy17q5SAFua3pt5zg5hHShuEUE6J1AFhCvyQrNez2h8Rytml90We-5ABckJteu0VV0xz4SREwAHhPw4r3zt9jBJ5Bbq5RDcjtyhKdDP281KwUsgBuUbfLi1Q4zp2wMqX_cqXf6388X8MckK2ui2A5bJPyXrbLPwZ2bCfbTVvzuOm-gbihM47
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Current+trends+in+the+immunotherapy+of+metastatic+and+recurrent+squamous+cell+carcinoma+of+the+head+and+neck&rft.jtitle=Opukholi+golovy+i+shei&rft.au=Yu.+V.+Kostalanova&rft.au=K.+A.+Ganina&rft.au=A.+A.+Makhonin&rft.au=A.+G.+Gabrielyan&rft.date=2020-11-16&rft.pub=ABV-press&rft.issn=2222-1468&rft.eissn=2411-4634&rft.volume=10&rft.issue=3&rft.spage=41&rft.epage=47&rft_id=info:doi/10.17650%2F2222-1468-2020-10-3-41-47&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_bfa0cea0535e461db7bef1cb9adff8c1
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2222-1468&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2222-1468&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2222-1468&client=summon